Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash & Current Investments: 2010-2025

Historic Cash & Current Investments for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $919.4 million.

  • Arrowhead Pharmaceuticals' Cash & Current Investments rose 35.01% to $919.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 billion, marking a year-over-year increase of 86.46%. This contributed to the annual value of $919.4 million for FY2025, which is 35.01% up from last year.
  • As of FY2025, Arrowhead Pharmaceuticals' Cash & Current Investments stood at $919.4 million, which was up 35.01% from $681.0 million recorded in FY2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Cash & Current Investments peaked at $919.4 million during FY2025, and registered a low of $311.2 million during FY2021.
  • In the last 3 years, Arrowhead Pharmaceuticals' Cash & Current Investments had a median value of $681.0 million in 2024 and averaged $668.0 million.
  • Data for Arrowhead Pharmaceuticals' Cash & Current Investments shows a peak YoY soared of 68.71% (in 2024) over the last 5 years.
  • Arrowhead Pharmaceuticals' Cash & Current Investments (Yearly) stood at $311.2 million in 2021, then grew by 20.96% to $376.4 million in 2022, then rose by 7.23% to $403.6 million in 2023, then skyrocketed by 68.71% to $681.0 million in 2024, then skyrocketed by 35.01% to $919.4 million in 2025.